Advertisement

Special situations III: Medicines for Children

  • Christoph Male

Abstract

The majority of drugs have never been evaluated for use in children. Developmental differences between adults and children of different ages affect pharmacokinetics and pharmacodynamics, and the safety profile of drugs. Use of drugs without paediatric information carries risks such as inappropriate dosing, lack of efficacy, and unexpected adverse events. Paediatric drug studies have been hampered by ethical and legal restrictions, methodological challenges and economical restraints. Recently, regulatory initiatives to stimulate paediatric drug development have been implemented in the US and EU. The EU Paediatric Regulation “Better Medicines for Children” requires paediatric development according to a Paediatric Investigation Plan (PIP) for all new drugs and on-patent drugs when applying for an authorization extension. Paediatric development is rewarded with a 6-months patent extension. PIPs are reviewed and amended by a Paediatric Committee at the European Medicines Agency. Certain collateral measures are included that are intended to improve information, transparency, and to stimulate research into paediatric medicines. Key points to consider for a PIP such as the definition of relevant paediatric indications(s), development of age- appropriate formulation(s), juvenile animal studies, paediatric PK and PD studies, and clinical efficacy and safely studies are discussed. A case study on a PIP is provided.

Keywords

Developmental pharmacological differences EU Paediatric Regulation Paediatric Investigation Plan inventory of paediatric therapeutic needs age-appropriate formulation juvenile animal studies physiologically-based PK model population PK extrapolation 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Wilson JT (1999) An update on the therapeutic orphan. Pediatrics 104: 585–590PubMedGoogle Scholar
  2. 2.
    Turner S, Gill A, Nunn T, Hewitt B, Choonara I (1996) Use of ‘off-label’ and unlicensed drugs in paediatric intensive care unit. Lancet 347: 549–550PubMedCrossRefGoogle Scholar
  3. 3.
    Conroy S, McIntyre J, Choonara I (1999) Unlicensed and off label drug use in the neonate. Arch Dis Child Fetal Neonatal Ed 80: F142–F145PubMedCrossRefGoogle Scholar
  4. 4.
    Conroy S, Choonara I, Impicciatore P, Mohn A, Arnell H, Rane A, Knoeppel C, Seyberth H, Pandolfini C, Raffaelli MP, Rocchi F, Bonati M, Jong G, de Hoog M, van den Anker J (2000) on behalf of the European Network for Drug Investigation in Children. Survey of unlicensed and off label drug use in paediatric wards in European countries. BMJ 320: 79–82PubMedCrossRefGoogle Scholar
  5. 5.
    ’T Jong GW, Eland IA, Sturkenboom MC, van den Anker JN, Stricker BH (2002) Unlicensed and off-label prescription of drugs to children: a population based cohort study. BMJ 324: 1313–1314CrossRefGoogle Scholar
  6. 6.
    Lindell-Osuagwu L, Korhonen MJ, Saano S, Helin-Tanninen M, Naaranlahti T, Kokki H (2009) Off-label and unlicensed drug prescribing in three paediatric wards in Finland and review of the international literature. J Clin Pharm Ther 34: 277–287PubMedCrossRefGoogle Scholar
  7. 7.
    Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE (2003) Developmental pharmacology: drug disposition, action, and therapy in infants and children. N Engl J Med 349: 1157–1167PubMedCrossRefGoogle Scholar
  8. 8.
    Johnson TN (2005) Modelling approaches to dose estimation in children. Br J Clin Pharmacol 59(6): 663–669PubMedCrossRefGoogle Scholar
  9. 9.
    Sutherland JM (1959) Fatal cardiovascular collapse of infants receiving large amounts of chloramphenicol. AMA J Dis Child 97: 761–767PubMedGoogle Scholar
  10. 10.
    Horen B, Montastruc J, Lapeyre-Mestre M (2002) Adversedrug reactions and off-label drug use in paediatric outpatients. Br J Clin Pharmacol 54: 665–670PubMedCrossRefGoogle Scholar
  11. 11.
    Turner S, Nunn AJ, Fielding K, Choonara I (1999) Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: a prospective study. Acta Paediatr 88: 965–968PubMedCrossRefGoogle Scholar
  12. 12.
    European Parliament (2001) Directive 2001/20/EC of the European Parliament and Council of 4 April 2001. Official Journal of the European Communities L121: 34–44Google Scholar
  13. 13.
    Kauffman RE (2000) Clinical trials in children: problems and pitfalls. Paediatr Drugs 2: 411–418PubMedCrossRefGoogle Scholar
  14. 14.
    US Food and Drug Administration (2007) Pediatric Research Equity Act (PREA) and Best Pharmaceuticals for Children Act (BPCA). http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM049870.pdf (accessed 2010-04-24)
  15. 15.
    Benjamin DK Jr, Smith PB, Murphy MD, et al. (2006) Peer-reviewed publication of clinical trials completed for pediatric exclusivity. JAMA 296: 1266–1273PubMedCrossRefGoogle Scholar
  16. 16.
    Regulation (EC) Nol901/2006 and 1902/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use (2006). Paediatric regulation. Official J Eur Union 18: L378/1Google Scholar
  17. 17.
    European Medicines Agency, PDCO press release March 2010, http://www.ema.europa.eu/pdfs/human/pdco/15139110en.pdf (accessed 2010-04-24)
  18. 18.
    European Medicines Agency (2007) Inventory of Paediatric Needs. http://www.emea.europa.eu/htms/human/paediatrics/inventory.htm (accessed 2010-04-24)
  19. 19.
    International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) (2000) Clinical Investigation of Medicinal Products in the Pediatric Population, E11Google Scholar
  20. 20.
    European Medicines Agency, Committee for Medicinal Products for Human Use (2006) Reflection paper: formulations of choice for the Paediatric population, EMEA/CHMP/PEG/ 194810/2005Google Scholar
  21. 21.
    European Medicines Agency, Committee for Human Medicinal Products (2008) Guideline on the Need for Non-clinical Testing in Juvenile Animals on Human Pharmaceuticals for Paediatric Indications, EMEA/CHMP/SWP/169215/2005Google Scholar
  22. 22.
    De Schaepdrivjer LM, Bailey GP (2009) Preclinical juvenile toxicity assessments and study designs. In: Mulberg AE, Silber SA, van den Anker JN (eds.) Paediatric Drug Development, Concepts and Applications. Wiley-Blackwell, Hoboken, New JerseyGoogle Scholar
  23. 23.
    European Medicines Agency, Committee for Medicinal Products for Human Use (2006) Guideline on the role of pharmacokinetics in the development of medicinal products in the paediatric population. EMEA/CHMP/EWP/147013/2004Google Scholar
  24. 24.
    Manolis E, Pons G (2009) Proposals for model based paediatric medicinal development within the current EU regulatory framework. Br J Clin Pharmacol 68: 493–501PubMedCrossRefGoogle Scholar
  25. 25.
    Björkman S (2004) Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs. Br J Clin Pharmacol 59: 691–704CrossRefGoogle Scholar
  26. 26.
    Anderson BJ, Allegaert K, Holford NH (2006) Population clinical pharmacology of children: general principles. Eur J Pediatr 165: 741–746PubMedCrossRefGoogle Scholar
  27. 27.
    US Food and Drug Administration, CDER. Pediatric Decision Tree. http://www.fda.gov/cder/mapp/4000.4.pdf (27 April 2004)
  28. 28.
    Savi P, Nurden P, Nurden AT, Levy-Toledano S, Herbert JM (1998) Clopidogrel: a review of its mechanism of action. Platelets 9: 251–255PubMedCrossRefGoogle Scholar
  29. 29.
    Li JS, Yow E, Berezny KY, Rhodes JF, Bokesch PM, Charpie JR, Forbus GA, Mahony L, Boshkov L, Lambert V, Bonnet D, Michel-Behnke I, Graham TP, Takahashi M, Jaggers J, Califf RM, Rakhit A, Fontecave S, Sanders SP (2007) Clinical outcomes of palliative surgery including a systemic to-pulmonary artery shunt in infants with cyanotic congenital heart disease: does aspirin make a difference? Circulation 116: 293–297PubMedCrossRefGoogle Scholar
  30. 30.
    Monagle P, Chalmers E, Chan A, deVeber G, Kirkham F, Massicotte P, Michelson AD (2008) Antithrombotic therapy in neonates and children: American college of chest guidelines (8th edition) physicians evidence-based clinical practice. Chest 133: 887–968CrossRefGoogle Scholar
  31. 31.
    US Food and Drug Administration (2010) Written requests issued. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm050002.htm (accessed 2010-04-24)
  32. 32.
    European Medicines Agency (2008) Clopidogrel (Plavix) PDCO opinion, EMEA-000049-PIP01-07-M01 P/122/2008. http://www.ema.europa.eu/htms/human/paediatrics/decisions.htm (accessed 2010-04-24)
  33. 33.
    Li J, Yow E, Berezny KY, Bokesch PM, Takahashi M, Graham TP, Sanders SP, Sidi D, Bonnet D, Ewert P, Jennings LK, Michelson AD, for the PICOLO Investigators (2008) Dosing of clopidogrel for platelet inhibition in infants and young children: primary results of the Platelet Inhibition in Children On cLOpidogrel (PICOLO) Trial. Circulation 117: 553–559PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag/Wien 2010

Authors and Affiliations

  • Christoph Male
    • 1
  1. 1.Department of PaediatricsMedical University of ViennaViennaAustria

Personalised recommendations